DOI QR코드

DOI QR Code

Thyroid Transcription Factor-1 Expression in Advanced Non-Small Cell Lung Cancer: Impact on Survival Outcome

  • Elsamany, Shereef Ahmed (Department of Medical Oncology, Oncology Centre, King Abdulaziz Medical City) ;
  • Al-Fayea, Turki M (King Abdulaziz Medical City) ;
  • Alzahrani, Abdullah Said (Department of Medical Oncology, Oncology Centre, King Abdulaziz Medical City) ;
  • Abozeed, Waleed Nabeel (Department of Clinical Oncology, Mansoura University Hospital) ;
  • Darwish, Waseem (King Abdulaziz Medical City) ;
  • Farooq, Mian Usman (Department of Research, King Abdullah Medical City) ;
  • Almadani, Ahmed Salahuddin (Department of Research, Um Alqora University) ;
  • Bukhari, Esraa Ahmed (Department of Research, Um Alqora University)
  • Published : 2015.04.14

Abstract

Background: The prognostic role of thyroid transcription factor-1 (TTF-1) expression in lung cancer has been assessed but with inconsistent results. The present study aimed to evaluate the prognostic value of TTF1 expression in advanced non-squamous non-small cell lung cancer (NSCLC). Materials and Methods: In this retrospective study, patients with stage IIIB-IV non-squamous NSCLC were enrolled. Progression free survival (PFS) and overall survival (OS) were assessed according to TTF1 expression status, age categories (${\leq}60$ vs >60 years), gender, performance status (PS) (0-2 vs 3-4), type of 1st line chemotherapy (pemetrexed containing vs others) and EGFR status. Results: A total of 120 patients were included. In univariate analysis, PFS was improved in patients with PS 0-2 (7.0 vs 2.0 months, p=0.002) and those who received pemetrexed-containing chemotherapy (9.2 vs 5.8 months, p=0.004). OS was improved in female patients (23.0 vs 8.7 months, p<0.0001), PS 0-2 (14.4 vs 2.0 months, p<0.0001), those with pemetrexed-containing chemotherapy (17.0 vs 11.0 months, p=0.019), TTF1-positive (12.8 vs 5.8 months, p=0.011) and EGFR- mutant patients (23.0 vs 11.7 months, p=0.006). In multivariate analysis, male gender (HR=2.34, p=0.025) and non-pemetrexed containing therapy (HR=2.24, p=0.022) were independent predictors of worse PFS. Wild EGFR status (HR=2.49, p=0.015) and male gender (HR=2.78, p=0.008) were predictors of worse OS. Conclusions: Pemetrexed-containing therapy significantly improved PFS while OS was improved in EGFR mutant patients. Female patients had better PFS and OS. TTF1 expression was not a prognostic marker in advanced non-squamous NSCLC.

Keywords

TTF1;prognosis;advanced;lung cancer

References

  1. Anagnostou VK, Syrigos KN, Bepler G, Homer RJ, Rimm DL (2009). Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol, 27, 271-8. https://doi.org/10.1200/JCO.2008.17.0043
  2. Barlesi F, Pinot D, Legoffic A, et al (2005). Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung. Br J Cancer, 93, 450-2. https://doi.org/10.1038/sj.bjc.6602717
  3. Berghmans T, Paesmans M, Mascaux C, et al (2006). Thyroid transcription factor 1: a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol, 17, 1673-6. https://doi.org/10.1093/annonc/mdl287
  4. Cao W, Li AW, Ren SX, et al (2014). Efficacy of first-line chemotherapy affects the second-line setting response in patients with advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 6799-804. https://doi.org/10.7314/APJCP.2014.15.16.6799
  5. Chung KP, Huang YT, Chang YL, et al (2012). Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment. Chest, 141, 420-8. https://doi.org/10.1378/chest.10-3149
  6. Haque AK, Syed S, Lele SM, Freeman DH, Adegboyega PA (2002). Immunohistochemical study of thyroid transcription factor-1 and HER2/neu in non-small cell lung cancer: Strong thyroid transcription factor-1 expression predicts better survival. Appl Immunohistochem Mol Morphol, 10, 103-9.
  7. Hoffman PC, Mauer AM, Vokes EE (2000). Lung cancer. Lancet, 355, 479-85. https://doi.org/10.1016/S0140-6736(00)82038-3
  8. Hotta K, Matsuo K, Ueoka H, et al (2004). Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: Reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol, 22, 3860-7. https://doi.org/10.1200/JCO.2004.01.153
  9. Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients. Asian Pac J Cancer Prev, 13, 301-4. https://doi.org/10.7314/APJCP.2012.13.1.301
  10. Liu YC, Zhou SB, Gao F, et al (2013). Chemotherapy and late course three dimensional conformal radiotherapy for treatment of patients with stage III non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 2663-5. https://doi.org/10.7314/APJCP.2013.14.4.2663
  11. Martins SJ, Takagaki TY, Silva AG, et al (2009). Prognostic relevance of TTF-1 and MMP-9 expression in advanced lung adenocarcinoma. Lung Cancer, 64, 105-9. https://doi.org/10.1016/j.lungcan.2008.07.017
  12. Pelosi G, Fraggetta F, Pasini F, et al (2001). Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas ofthe lung. Am J Surg Pathol, 25, 363-72. https://doi.org/10.1097/00000478-200103000-00011
  13. Saad RS, Liu YL, Han H, Landreneau RJ, Silverman JF (2004). Prognostic significance of thyroid transcription factor-1 expression in both early-stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. Hum Pathol, 35, 3-7. https://doi.org/10.1016/j.humpath.2003.08.011
  14. Stenhouse G, Fyfe N, King G, Chapman A, Kerr KM (2004). Thyroid transcription factor 1 in pulmonary adenocarcinoma. J Clin Pathol, 57, 383-7. https://doi.org/10.1136/jcp.2003.007138
  15. Sun JM, Han J, Ahn JS, Han JH, Ahn M (2011). Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol, 6, 1392-9. https://doi.org/10.1097/JTO.0b013e3182208ea8
  16. Tan D, Li Q, Deeb G, et al (2003). Thyroid transcription factor-1 expression prevalence and its clinical implications in nonsmall cell lung cancer: A high throughput tissue microarray and immunohistochemistry study. Hum Pathol, 34, 597-604. https://doi.org/10.1016/S0046-8177(03)00180-1
  17. Tanaka H, Yanagisawa K, Shinjo K, et al (2007). Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res, 67, 6007-11. https://doi.org/10.1158/0008-5472.CAN-06-4774
  18. Wang JY, Cai Y (2013). Clinical observation and prognostic analysis of pemetrexed plus platinum as first-line treatment in patients with advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 6267-71. https://doi.org/10.7314/APJCP.2013.14.11.6267
  19. Zhan P, Qian Q, Wan B, Yan TD, Yu LK (2013). Prognostic value of TTF-1 expression in patients with non-small cell lung cancer: a meta-analysis. Transl Cancer Res, 2, 25-32.

Cited by

  1. Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy vol.39, pp.2, 2017, https://doi.org/10.1177/1010428317691186
  2. Relationship between Expression of TTF-1, TS and Chemotherapy Effect of Pemetrexed in Advanced Lung Adenocarcinoma vol.08, pp.01, 2018, https://doi.org/10.12677/WJCR.2018.81004
  3. Absence of thyroid transcription factor-1 expression is associated with poor survival in patients with advanced pulmonary adenocarcinoma treated with pemetrexed-based chemotherapy pp.1863-4362, 2018, https://doi.org/10.1007/s11845-018-1839-5